One hundred eighty-four patients with breast cancer received neoadjuvant chemotherapy [14, 16], and 81 with colorectal cancer received palliative chemotherapy with or without cetuximab, an epidermal growth factor receptor monoclonal antibody [15, 17]. The gene discussed is EGFR; the disease is breast cancer.